| scholarly article | Q13442814 |
| P50 | author | Marina Konopleva | Q89564940 |
| Juliana M Benito | Q114427925 | ||
| Borys Korchin | Q114427988 | ||
| Jorge Eduardo Cortes | Q60320900 | ||
| Hagop Kantarjian | Q60394812 | ||
| Arthur E. Frankel | Q62695282 | ||
| Michael Andreeff | Q66385504 | ||
| P2093 | author name string | Rui-Yu Wang | |
| Eric K Rowinsky | |||
| Chris Brooks | |||
| Olga Frolova | |||
| P2860 | cites work | Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys | Q80569242 |
| Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia | Q80766143 | ||
| Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors | Q82606646 | ||
| The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells | Q28140494 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML | Q29614278 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. | Q33178852 | ||
| A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol | Q34084084 | ||
| Gene expression changes associated with progression and response in chronic myeloid leukemia | Q34479561 | ||
| BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia | Q34651708 | ||
| The role of interleukin-3 in classical Hodgkin's disease. | Q35994955 | ||
| Tumour-initiating cells: challenges and opportunities for anticancer drug discovery | Q37606286 | ||
| Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells | Q37697847 | ||
| Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor | Q38308860 | ||
| High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial | Q38379888 | ||
| Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells | Q39040925 | ||
| Imaging cartilage physiology. | Q40231309 | ||
| Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors | Q40393545 | ||
| Outcome of patients with acute myelogenous leukemia after second salvage therapy | Q40411708 | ||
| Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies | Q40531685 | ||
| Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity | Q40581960 | ||
| The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex | Q40659678 | ||
| Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line | Q40692679 | ||
| Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice | Q40804297 | ||
| Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity | Q41356541 | ||
| Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression | Q41897967 | ||
| Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. | Q42143237 | ||
| A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia | Q43170869 | ||
| Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials | Q43270688 | ||
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro | Q43833442 | ||
| Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment | Q44308354 | ||
| Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. | Q44389000 | ||
| Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction | Q46937459 | ||
| Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia | Q47633694 | ||
| BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. | Q51141709 | ||
| Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy. | Q53606061 | ||
| Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. | Q53646273 | ||
| Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. | Q53957613 | ||
| Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate | Q60021753 | ||
| Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells | Q60490274 | ||
| Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias | Q73674673 | ||
| Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines | Q73774745 | ||
| Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein | Q73821436 | ||
| Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission | Q73851048 | ||
| Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression | Q77557536 | ||
| A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors | Q77815927 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| tagraxofusp-erzs | Q60666292 | ||
| P304 | page(s) | 862-874 | |
| P577 | publication date | 2014-06-19 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia | |
| P478 | volume | 166 |
| Q48158203 | A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. |
| Q51016220 | A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. |
| Q53629318 | Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells. |
| Q98719933 | Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm |
| Q90231866 | CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies |
| Q58557050 | CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia |
| Q37422094 | CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. |
| Q52633239 | DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia. |
| Q38737657 | Design, synthesis and evaluation of anti-CD123 antibody drug conjugates |
| Q62820095 | High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression |
| Q36618978 | ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro |
| Q93017003 | Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML |
| Q33588245 | Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth |
| Q38767908 | Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase |
| Q39411920 | Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors |
| Q50581082 | Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. |
| Q39440164 | Role of the β Common (βc) Family of Cytokines in Health and Disease |
| Q38761791 | Stem and progenitor cell alterations in myelodysplastic syndromes |
| Q52375473 | Targeting Leukemia Stem Cells in the Bone Marrow Niche. |
| Q39265778 | The biomarkers of leukemia stem cells in acute myeloid leukemia |
| Q38787790 | Treatment of blastic plasmacytoid dendritic cell neoplasm |
| Q34784895 | Use of proteins as biomarkers and their role in carcinogenesis. |
Search more.